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ABSTRACT
Cabergoline is a new long-acting dopamine agonist that is very
effective and well tolerated in patients with pathological hyperpro-
lactinemia. The aim of this study was to examine, in a very large
number of hyperprolactinemic patients, the ability to normalize PRL
levels with cabergoline, to determine the effective dose and tolerance,
and to assess the effect on clinical symptoms, tumor shrinkage, and
visual field abnormalities. We also evaluated the effects of cabergoline
in a large subgroup of patients with bromocriptine intolerance or
-resistance.
We retrospectively reviewed the files of 455 patients (102 males
and 353 females) with pathological hyperprolactinemia treated with
cabergoline in 9 Belgian centers. Among these patients, 41% had a
microadenoma; 42%, a macroadenoma; 16%, idiopathic hyperpro-
lactinemia; and 1%, an empty sella. The median pretreatment serum
PRL level was 124 mg/L (range, 16–26,250 mg/L). A subgroup of 292
patients had previously been treated with bromocriptine, of which 140
showed bromocriptine intolerance and 58 showed bromocriptine
resistance.
Treatment with cabergoline normalized serum PRL levels in 86%
of all patients: in 92% of 244 patients with idiopathic hyperprolactine-
mia or a microprolactinoma and in 77% of 181 macroadenomas. Pre-
treatment visual field abnormalities normalized in 70% of patients,
and tumor shrinkage was seen in 67% of cases. Side effects were noted
in 13% of patients, but only 3.9% discontinued therapy because of side
effects. The median dose of cabergoline at the start of therapy was 1.0
mg/week but could be reduced to 0.5 mg/week once control was
achieved. Patients with a macroprolactinoma needed a higher median
cabergoline dose, compared with those with idiopathic hyperpro-
lactinemia or a microprolactinoma: 1.0 mg/week vs. 0.5 mg/week,
although a large overlap existed between these groups. Twenty-seven
women treated with cabergoline became pregnant, and 25 delivered
a healthy child. One patient had an intended abortion and another a
miscarriage. In the patients with bromocriptine intolerance, normal-
ization of PRL was reached in 84% of cases, whereas in the bro-
mocriptine-resistant patients, PRL could be normalized in 70%.
We confirmed, in a large-scale retrospective study, the high efficacy
and tolerability of cabergoline in the treatment of pathological hy-
perprolactinemia, leaving few patients with unacceptable side effects
or inadequate clinical response. Patients with idiopathic hyperpro-
lactinemia or a microprolactinoma, on average, needed only half the
dose of cabergoline as those with macroprolactinomas and have a
higher chance of obtaining PRL normalization. Cabergoline also nor-
malized PRL in the majority of patients with known bromocriptine
intolerance or -resistance. Once PRL secretion was adequately con-
trolled, the dose of cabergoline could often be significantly decreased,
which further reduced costs of therapy. (J Clin Endocrinol Metab 84:
2518–2522, 1999)
DOPAMINE AGONISTS are the first-line treatment forthe majority of patients with hyperprolactinemic dis-
orders (1). Bromocriptine, introduced in 1971, is the original
preparation against which newer dopamine agonists are
compared. It is effective in suppressing PRL hypersecretion,
reducing prolactinoma size, and restoring gonadal function
(2). However, a significant proportion of patients (up to 20%)
does not tolerate the drug at therapeutic doses or is resistant.
In addition, because of a short half-life, bromocriptine usu-
ally has to be taken twice or three times a day, making it less
convenient for long-term therapy. Cabergoline, another er-
got derivative, has been developed to overcome these dis-
advantages. With duration of action up to 14 days after a
single dose, cabergoline needs to be taken only once or twice
weekly (3). In a large comparative double-blind study in
female patients with idiopathic hyperprolactinemia or a mi-
croprolactinoma, cabergoline was significantly more effec-
tive than bromocriptine in suppressing PRL secretion and
restoring the menstrual cycle and had a slightly superior
tolerability (4). Similarly, better results were obtained with
cabergoline, compared with bromocriptine, in macropro-
lactinomas (5–7). Also, in males, cabergoline restored sexual
function and fertility earlier than bromocriptine (8). Finally,
a majority of patients intolerant or resistant to bromocriptine
responded adequately to cabergoline (9–11). Because the
number of clinical studies with cabergoline is still limited,
compared with data collected with bromocriptine, we ret-
rospectively analyzed our own experience with cabergoline
in a very large cohort of patients with pathological hyper-
prolactinemia. We examined baseline characteristics predict-
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ing success of treatment and the average maintenance dose
of the drug necessary to control PRL levels according to the
cause of hyperprolactinemia. We also determined the effects
of cabergoline in a large subgroup of patients not responding
well to bromocriptine because of resistance or intolerance.
Subjects and Methods
Subjects
Cabergoline [Dostinex (Sostilar in Belgium), Pharmacia & Upjohn,
Inc., Brussels, Belgium] has been available for compassionate use in
hyperprolactinemic patients in Belgium since 1989. Whereas, initially,
only patients resistant or intolerant to bromocriptine were treated with
cabergoline, the drug became recently available for all patients with
pathological hyperprolactinemia. We retrospectively reviewed the files
of 455 patients [102 (22%) males and 353 (78%) females] with patho-
logical hyperprolactinemia, treated (on a compassionate-need basis)
with cabergoline, in 9 Belgian centers. Based on the amount of medi-
cation provided by the manufacturer, this cohort was estimated to be
close to 90% of all patients treated with cabergoline for hyperprolactine-
mia in Belgium. The median basal PRL serum level was 124 mg/L; range,
16–26250 mg/L. Secondary hyperprolactinemia, caused by medication,
and hypothyroidism or pituitary stalk compression were excluded (the
latter based upon radiological imaging, pathological examination (in
case of surgery), or a PRL cutoff value of 200 ng/mL). At diagnosis, 174
(41%) of patients had a microadenoma; 181 (42%), a macroadenoma; 70
(16%), an idiopathic hyperprolactinemia; and 5 (1%), an empty sella.
Data on tumor volume was missing or inaccessible in 25 patients (6%).
A total of 116 (25%) patients had surgery, and 14 (3.1%) had radiother-
apy, before starting cabergoline, after a median delay of 42 months
(range, 1–204 months) and 32 months (range, 7–121 months), respec-
tively. Of all patients, 34 (8.7%) had associated ACTH deficiency, 35
(8.4%) had TSH deficiency, 57 (15%) had GH deficiency, and 1 (0.3%) had
diabetes insipidus. Sixty-four patients (14%) had visual field defects; 71
(16%) had symptoms of migraine. Of the 292 patients previously treated
with bromocriptine, 198 were changed to cabergoline because of resis-
tance (58 patients) or intolerance (140 patients) to bromocriptine, 16
because of a combination of resistance and intolerance, and 78 for var-
ious other reasons (usually convenience or better compliance). Details of
the patient characteristics are given in Table 1.
Study design
Cabergoline was usually started at a dose of 0.25 mg or 0.5 mg twice
weekly. A dose adaptation was made every 2 or 3 months, until stabi-
lization, after which the patients were usually seen every 4–6 months.
Once a pronounced and stable suppression of the PRL levels was ob-
tained, the dose of cabergoline was often reduced. Whenever pregnancy
occurred or was planned, cabergoline was discontinued until after de-
livery. From the files, the following data were retrieved: basal symp-
toms, initial PRL level, basal tumor volume with dimensions, category
of tumor volume (micro- and macroadenoma, empty sella), additional
pituitary deficiencies, previous treatments (surgery, radiotherapy), and
additional pathology. Data retrieved during cabergoline treatment were:
reason for starting therapy, date of start of treatment, pretreatment PRL
level, nadir PRL level, clinical effects, drug dose after reaching nadir
PRL, drug dose at the time of evaluation, evolution of tumor volume
(with dimensions and estimated shrinkage), duration of therapy, re-
ported side effects, reason of discontinuing therapy, pregnancy, and
fetal outcome. Tumor volume was evaluated by computed tomography
scanning (8%) or magnetic resonance imaging examination (92%). Evo-
lution of tumor size was estimated by the radiologist in each center, by
comparing directly the initial with the latest radiographic documents.
Patients were treated with cabergoline for a median of 28 months (range,
1–99 months). In the subgroup of patients previously treated with bro-
mocriptine, 99 were changed to cabergoline without a prolonged wash-
out period. In these patients, changes of PRL levels or symptoms were
evaluated, compared with baseline values.
Hormone assays
Serum PRL and other hormones were measured with commercially
available kits (immunoradiometric, immunoenzymatic, or RIA. The up-
per range of normal, for serum PRL concentration, was considered less
than 10 mg/L in males and less than 20 mg/L in females. The converting
factor for PRL was: 33.6 mU/L 5 1 mg/L.
Statistics
Because data on PRL levels and dose of medication did not follow a
normal distribution, all results are expressed in median levels, with the
total range or first (Q1) and third (Q3) quartiles. If the number of patients
with certain clinical effects or side effects is given, both the absolute
number and percentage of all patients are reported. Statistical differ-
ences were calculated with nonparametrical tests, and the limit of sig-
nificance was considered as P , 0.05.
Results
Clinical response
Normalization of the menstrual cycle was obtained in 227
of 254 (89%) females in whom it was assessable. Twenty-
seven of these patients became pregnant under therapy with
cabergoline, and 25 delivered a healthy child. One patient
had a miscarriage, and the other had a deliberate abortion.
Excluded from this analysis were 99 female patients, either
menopausal (47 patients), having undergone hysterectomy,
on estrogen therapy, or with insufficient clinical data. Nor-
malization of libido and potency was noted in 46 (81%) of 57
males in whom it could be evaluated. Excluded were males
with normal libido at baseline (19 patients) or with insuffi-
cient clinical data (26 patients). Normalization of visual fields
was demonstrated in 33 of 47 (70%) patients. In 7 of 14 (50%)
patients without visual field improvement, this was consid-
ered to be the result of absent tumor shrinkage; in 4, the result
of insufficient shrinkage (,25%); and in 3, the result of ir-
reversible damage to the chiasm. Symptoms of migraine
significantly improved in 51 of 71 patients (72%).
PRL secretion
Normalization of PRL levels was achieved in 379 of 440
(86%) patients and a PRL decrease of at least 75% was ob-
tained in 34 (56%) of the remaining 61 patients. Data from 15
patients were not available for analysis of biochemical effi-
TABLE 1. Baseline characteristics of 455 hyperprolactinemic
patients treated with cabergoline
Characteristic Alln 5 455
Previously treated
with bromocriptine
n 5 292
Gender 102 M/353 F 60 M/232 F
Agea (yr) 35.9 6 13.5 34.2 6 12.3
Visual field defect 64 42
Baseline serum prolactinb
(mg/L)
124 (16–26250) 145 (16–12440)
Surgery 116 92
Radiotherapy 14 12
Idiopathic hyperprolactinemia 70 43
Microadenoma 174 116
Macroadenoma 181 110
Empty sella 5 3
Otherc 25 20
M, Male; F, female.
a Values are means 6 SD.
b Results are expressed by the median, with the first and third
quartiles between parenthesis.
c Unknown etiology or unknown size.
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cacy because of premature stop of therapy because of side
effects (4 patients), pregnancy (2 patients), or noncompliance
(9 patients). The median serum PRL nadir attained was 5.6
mg/L (Q1-Q3: 2.0–11.4 mg/L; range, 1.0–1250 mg/L), indi-
cating that most patients were well controlled. The time span
between the start of therapy and the PRL nadir was 8 months
(Q1-Q3: 3–20 months). In addition to the time required for
therapeutic effect of the drug, this interval also depended on
follow-up visit time interval, patient compliance, and drug
tolerance. No patient escaped therapy once control was
achieved.
Pituitary tumor size
The effect of cabergoline on tumor volume could be eval-
uated in 190 patients. Reasons for exclusion were idiopathic
hyperprolactinemia (70 patients), empty sella (5 patients),
absence of initial computed tomography scanning or mag-
netic resonance imaging examination (25 patients), microad-
enomas of too-small volume for meaningful evaluation of
shrinkage, or absent control iconography. A more-than-50%
decrease of tumor volume was seen in 58 (31%) patients,
between 25 and 50% in 30 (16%) patients, and less than 25%
in another 39 (21%). Altogether, a total of 67% of patients
showed some degree of tumor shrinkage.
Cabergoline dose
In accordance with the standard dose recommended by
the manufacturer, the median starting dose of cabergoline
was 1.0 mg/week in two gifts (Q1-Q3: 0.5–1.5 mg/week). In
103 patients (25%), the maintenance dose of cabergoline
could be reduced without deterioration of PRL control, so
that the median cabergoline dose was 0.5 mg/week (Q1-Q3:
0.25–1.0 mg/week) at the end of the evaluation period. The
scheme of dose for patients is shown in Table 2. In the
cabergoline-resistant patients, the dose of cabergoline was
increased to a median of 3.5 mg/week (range, 1.5–7.0
mg/week).
Tolerance
Of all 455 patients, 38 (8.5%) reported minor dopamine
agonist-related side effects; and 18 (4%), major or persisting
symptoms. Most prominent complaints were headache (16
patients), postural hypotension (10 patients), nausea (8 pa-
tients), and sleepiness (6 patients). Fourteen (3.9%) patients
stopped therapy because of intolerance of cabergoline. Of
these, 12 had been intolerant to bromocriptine, as well.
Subgroup analysis
Micro- vs. macroprolactinomas. In patients with a micropro-
lactinoma, the probability of reaching normal PRL levels was
significantly higher than in patients with a macroprolacti-
noma [respectively, 93% vs. 77% (P , 0.001)], whereas no
difference was found between microprolactinoma and idio-
pathic hyperprolactinemia (93% vs. 91%, mean of both
groups 92%). Patients with a microprolactinoma needed sig-
nificantly lower doses of cabergoline, compared with pa-
tients with a macroprolactinoma (median, 0.5 mg/week; Q1-
Q3: 0.25–1.0 mg/week vs. 1.0 mg/week; Q1-Q3: 0.5–1.5 mg/
week, P 5 0.003), although an overlap existed between the
two groups.
Male vs. female patients. Male patients had less likelihood of
achieving normal PRL levels than females: 75% vs. 90% (P 5
0.001). However, considering the fact that the large majority
of males had a macroprolactinoma (86% vs. 38% only for
females), gender had no independent influence on success
rates. When only microprolactinomas were considered, the
outcome was similar in males and females: 92% vs. 93%.
Basal PRL levels. A weak (but significant) correlation was
found between the basal PRL level and the nadir PRL level
(r 5 0.246, P , 0.001). If patients with idiopathic hyperpro-
lactinemia or those with a microprolactinoma are considered
separately, a closer correlation was found between basal PRL
value and nadir value (respectively, r 5 0.71 and r 5 0.79, P ,
0.001), whereas the correlation in macroprolactinomas was
similar, as for the whole group (r 5 0.231, P 5 0.002). Also,
a loose correlation was found between the basal PRL level
and the final dose of cabergoline (r 5 0.162, P 5 0.001).
Bromocriptine resistance. 70% of the 58 patients in whom bro-
mocriptine failed to normalize PRL were controlled with
cabergoline (16 patients with both intolerance and resistance
not included in this analysis). They were less likely to achieve
normal PRL levels with cabergoline than other patients were
(70% vs. 88%, P , 0.001) and needed higher doses of caber-
goline: median 1.5 mg/week (Q1-Q3: 0.5–3.0 mg/week) vs.
0.5 mg/week (Q1-Q3: 0.25–1.0 mg/week) (P , 0.001). Seven
(1.5%) patients, previously found to be resistant to bro-
mocriptine, were also completely resistant to cabergoline
(,50% decrease in PRL levels).
Bromocriptine intolerance. Twelve of 140 patients (8.6%) in-
tolerant for bromocriptine showed a similar intolerance for
cabergoline. In general, no significant difference was noted
for bromocriptine-intolerant patients in obtaining PRL nor-
malization, compared with others (84% vs. 87%, P 5 not
significant). The median dose of cabergoline was 0.5 mg/
week (Q1-Q3: 0.25–1.0 mg/week), a result similar to the
values observed in bromocriptine-tolerant or naive patients.
Naive vs. bromocriptine pretreated patients. Patients previously
treated with bromocriptine obtained slightly worse results
than those who were not (82% PRL normalization vs. 88%),
despite a similar percentage of macroprolactinomas (38% vs.
TABLE 2. Number and distribution of patients, according to primary and final cabergoline dose (mg/week)
Dose (mg/week) 0.125 0.25 0.5 0.75 1 1.5 1.75–3 3.5 .4
Primary dose 1 47 165 6 135 30 33 22 8
0.2% 10.5% 36.7% 1.3% 30.1% 6.7% 7.3% 4.9% 1.8%
Final dose 23 73 108 4 78 28 28 15 7
6.3% 20.1% 29.7% 1.1% 21.4% 7.7% 7.7% 4.1% 1.9%
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41%, P 5 not significant). This difference disappeared, how-
ever, if the number of bromocriptine-resistant patients was
taken into account.
Discussion
We confirmed, in a large group of patients, the beneficial
effects of cabergoline in hyperprolactinemic disorders. The
large cohort of patients and the prolonged treatment period
allowed for a close estimation of the general efficacy and side
effects of cabergoline in daily clinical practice. In addition,
the large number of patients made it possible to evaluate
cabergoline in different subgroups of patients and to draw
conclusions regarding predicted effects of therapy for spe-
cific patients. The limitations of the current study are: the
retrospective character of the analysis, and a selection bias of
bromocriptine-resistant and/or intolerant patients at the be-
ginning of enrollment.
Our percentage of success in attaining normal PRL levels
is very close to that reported in the literature (Table 3). We
reached a mean percentage of PRL normalization of 86%,
which falls within the margins of 81–93% success of other
studies with combined micro- and macroprolactinomas.
When data are split into micro- and macroprolactinomas, the
similarity is even more striking. With a percentage of success
for combined microprolactinomas and idiopathic hyperpro-
lactinemia of 92%, we had results similar to those of Webster
et al. (12) and Muratori et al. (13): respectively, 92 and 96%.
Our results and the previous ones are better than the refer-
ence double-blind study of Webster et al. (4), where the
success rate was only 83%, most likely because no upward
dose adaptations were allowed in this study. Comparing the
macroprolactinomas, our success rate of 77% is close to the
results of Biller et al. (5), Ferrari et al. (6), and Colao et al. (7),
reaching 61%, 73%, and 83% of success, respectively (Table
3).
Apart from initial tumor volume, a lower pretreatment
PRL concentration predicted a better chance for obtaining
PRL normalization. The worse results in macroadenomas
reflect the known difference in biological behavior between
micro- and macroprolactinomas (14).
As anticipated, poorer results were found in the subgroup
of bromocriptine-resistant patients, when compared with the
other patients. Although the exact mechanism to understand
dopamine resistance is not entirely clear, the finding of only
few dopamine receptor-binding sites in this group of patients
offers an attractive explanation (15). In bromocriptine-intol-
erant patients, on the other hand, a comparable score was
reached (84%), underlining the fact that intolerance has a
different physiopathological mechanism, compared with re-
sistance. Nevertheless, up to 70% of 58 bromocriptine-resis-
tant patients did benefit from cabergoline therapy. This is
similar to the observations of Jones et al. (9), Delgrange et al.
(10), and Colao et al. (11), with (respectively) 1, 2/3 (67%), and
15/18 (79%) of bromocriptine-resistant patients responding
well to therapy with cabergoline. Furthermore, 84% of pa-
tients considered poorly tolerant for bromocriptine were con-
trolled with cabergoline, and only 8.6% were similarly in-
tolerant for cabergoline. In agreement with this, 4 times more
patients treated with bromocriptine, under double-blind
conditions, discontinued therapy because of intolerance, as
opposed to cabergoline: 12% vs. 3% (4). The possibility to
offer effective medical therapy in the majority of bromocrip-
tine-resistant and/or intolerant patients or those with low
compliance will make additional surgery and/or radiother-
apy unnecessary in their situations. Cabergoline, therefore,
further extends the place of medical therapy as primary
treatment for prolactinomas. Furthermore, if less prolacti-
noma patients must undergo additional surgery and/or ra-
diotherapy, cabergoline will probably also decrease the in-
cidence of pituitary deficiency syndromes as a result of these
procedures in this group of patients.
Up to 69% of our patients had significant tumor shrinkage,
a result falling between limits of all other studies (48–83%),
although differences in what is considered significant shrink-
age and differences in selection of patients make exact com-
parisons hazardous (Table 3).
The number of side effects (13%) was relatively low, as can
be expected from a retrospective study in which only drug-
related symptoms were recorded. It is considerably lower
than the figure of 68% adverse events in the prospective
study of Webster et al. (4), where all events were systemat-
ically registered. The other studies show figures between
these limits: 4–52% (Table 3). Our data probably underesti-
mate the real number of side effects and reflect what is
TABLE 3. Overview of efficacy and tolerability of cabergoline in patients with hyperprolactinemic disorders
Year Author Micro-
a/
macroadenoma
% PRL
normalization
% Side
effects % Dropouts
% Tumor
reductionb
Bromocriptine-
resistant/intolerant Reference
1989 Ciccarelli 27/3 81% 48% 11% 71% 0/7 (20)
1989 Ferrari 38/8 85% 15% 0 83% (21)
1992 Ferrari 108/19 90% 23% 0 79% 10/1 (22)
1993 Webster 161/1 92% 40% 3% 0/27 (12)
1994 Webster 223/0 83% 68% 3% (4)
1995 Pascal-V. 60/0 93% 52% 3.3% (23)
1996 Biller 0/15 73% Minimal 0 73% 5/5 (5)
1997 Ferrari 0/65 61% 25% 4.7% 66% 16/32 (6)
1997 Muratori 26/0 96% 24% 0 68% (13)
1997 Colao 8/19 85% 22% 0 48% 27/0 (11)
1997 Colao 0/23 83% 4% 0 61% 6/2 (7)
Verhelst 249/181 86% 13% 3.9% 67% 58/140
a Includes idiopathic hyperprolactinemia and empty sella.
b Criteria on what is considered significant differs between studies, and the imaging studies are usually only performed on a subgroup of
patients.
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considered clinically meaningful in daily practice. Few pa-
tients (3.9%) stopped therapy with cabergoline because of
side effects, an observation similar to the results of other
studies (3–11% drop-outs), and our own experience in ac-
romegalic patients treated with high doses of cabergoline
(3.2%) (16).
The median effective maintenance dose in this study was 0.5
mg/week, and 56% of patients could ultimately be controlled
with 0.5 mg or lower doses per week. This is a lesser dose than
the dose employed in earlier studies, such as the large open
study of Webster et al. (12), where only 40% of patients received
0.5 mg/week or less. It is also half the dose recommended in the
product label (0.5 mg twice weekly). In the large double-blind
study comparing bromocriptine with cabergoline, almost all
patients received 1.0 mg/week or more, but no downward dose
adjustments were allowed (4). We argue for the fact that lower
average doses of cabergoline probably suffice to control PRL
levels in many patients and that, once PRL levels are suppressed
at the lower limit of normality, it seems wise to drop the dose
of cabergoline. A lower average dose will also reduce the cost
of this long-term therapy.
The maintenance dose was higher in macroprolactinomas,
compared with microprolactinomas (median, 1 mg/week vs.
0.5 mg/week), was loosely dependent on the initial PRL
level, and was significantly higher in patients with previ-
ously known bromocriptine resistance. In agreement with
our results, the study of Colao et al. (11) showed that the
median dose of cabergoline, in 24 of 27 bromocriptine-resis-
tant patients, was 1 mg/week or more. Other studies on
macroprolactinomas also showed the necessity of a larger
dose: in the study of Biller et al. (5), the median dose of
cabergoline was 1.0 mg/week, and only 4 of 15 patients
needed only 0.5 mg/week.
The experience with bromocriptine during pregnancy is
far more extensive than with cabergoline, so that, for women
requiring treatment for fertility, bromocriptine is still con-
sidered the treatment of choice in most centers. However,
recent data showed no detrimental effects of cabergoline on
fetal outcome (17–19). In this study, we report 25 uneventful
deliveries for patients treated with cabergoline at the time of
conception. No increased incidence of malformations was
found in the children. Whereas heretofore cabergoline was
substituted for bromocriptine in preparation for pregnancy,
this might be unnecessary in the future if further data can
confirm these encouraging findings.
In conclusion, we confirmed, in a large-scale retrospective
study, the high efficacy and tolerability of cabergoline in the
treatment of pathological hyperprolactinemia, leaving few
patients with unacceptable side effects or inadequate clinical
response. Patients with idiopathic hyperprolactinemia or a
microprolactinoma, on average, needed only half the dose of
cabergoline as macroprolactinomas; and they had a higher
chance of obtaining PRL normalization. Cabergoline also
normalized PRL in the majority of patients with known bro-
mocriptine intolerance or resistance. This outcome should
certainly be taken into account in cost-benefit studies. Once
PRL secretion was adequately controlled, the starting dose of
cabergoline could often be significantly decreased, which
will further reduce costs.
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